{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:06:00Z","timestamp":1762506360412},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,6,8]],"date-time":"2014-06-08T00:00:00Z","timestamp":1402185600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00280-014-2504-y","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T23:27:00Z","timestamp":1402442820000},"page":"303-307","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Enhanced skin toxicity associated with the combination of clofarabine plus cytarabine for the treatment of acute leukemia"],"prefix":"10.1007","volume":"74","author":[{"given":"Bingnan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Bolognia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Marks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Podoltsev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,8]]},"reference":[{"key":"2504_CR1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jaad.2008.05.018","volume":"59","author":"JL Bolognia","year":"2008","unstructured":"Bolognia JL, Cooper DL, Glusac EJ (2008) Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 59:524\u2013529","journal-title":"J Am Acad Dermatol"},{"key":"2504_CR2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1159\/000258880","volume":"77","author":"AD Lipworth","year":"2009","unstructured":"Lipworth AD, Robert C, Zhu AX (2009) Hand\u2013foot syndrome (hand\u2013foot skin reaction, palmar\u2013plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77:257\u2013271","journal-title":"Oncology"},{"key":"2504_CR3","doi-asserted-by":"crossref","first-page":"798","DOI":"10.7326\/0003-4819-101-6-798","volume":"101","author":"JJ Lokich","year":"1984","unstructured":"Lokich JJ, Moore C (1984) Chemotherapy-associated palmar\u2013plantar erythrodysesthesia syndrome. Ann Intern Med 101:798\u2013799","journal-title":"Ann Intern Med"},{"key":"2504_CR4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/j.1875-9114.1989.tb04099.x","volume":"9","author":"T Graves","year":"1989","unstructured":"Graves T, Hooks MA (1989) Drug-induced toxicities associated with high-dose cytosine arabinoside infusions. Pharmacotherapy 9:23\u201328","journal-title":"Pharmacotherapy"},{"key":"2504_CR5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<105::AID-AJH3>3.0.CO;2-W","volume":"58","author":"M Montillo","year":"1998","unstructured":"Montillo M, Mirto S, Petti MC et al (1998) Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 58:105\u2013109","journal-title":"Am J Hematol"},{"key":"2504_CR6","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.leu.2401066","volume":"12","author":"W Kern","year":"1998","unstructured":"Kern W, Aul C, Maschmeyer G et al (1998) Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12:1049\u20131055","journal-title":"Leukemia"},{"key":"2504_CR7","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1182\/blood.V62.2.361.361","volume":"62","author":"RH Herzig","year":"1983","unstructured":"Herzig RH, Wolff SN, Lazarus HM et al (1983) High-dose cytosine arabinoside therapy for refractory leukemia. Blood 62:361\u2013369","journal-title":"Blood"},{"key":"2504_CR8","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","volume":"105","author":"S Faderl","year":"2005","unstructured":"Faderl S, Gandhi V, O\u2019Brien S et al (2005) Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940\u2013947","journal-title":"Blood"},{"key":"2504_CR9","unstructured":"National cancer institute (2009) Common terminology criteria for adverse events v4.0. National cancer institute common terminology criteria for adverse events v40 NIH publication #09-7473: NCI, NIH, DHHS"},{"key":"2504_CR10","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0609.2011.01703.x","volume":"88","author":"S Buchholz","year":"2012","unstructured":"Buchholz S, Dammann E, Stadler M et al (2012) Cytoreductive treatment with clofarabine\/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome. Eur J Haematol 88:52\u201360","journal-title":"Eur J Haematol"},{"key":"2504_CR11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1159\/000338828","volume":"128","author":"YY Hwang","year":"2012","unstructured":"Hwang YY, Trendell-Smith NJ, Yeung CK et al (2012) Fatal palmar\u2013plantar erythrodysesthesia after clofarabine and cytarabine chemotherapy. Acta Haematol 128:151\u2013153","journal-title":"Acta Haematol"},{"key":"2504_CR12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","volume":"44","author":"R Moos von","year":"2008","unstructured":"von Moos R, Thuerlimann BJ, Aapro M et al (2008) Pegylated liposomal doxorubicin-associated hand\u2013foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44:781\u2013790","journal-title":"Eur J Cancer"},{"key":"2504_CR13","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","volume":"28","author":"YK Kang","year":"2010","unstructured":"Kang YK, Lee SS, Yoon DH et al (2010) Pyridoxine is not effective to prevent hand\u2013foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol 28:3824\u20133829","journal-title":"J Clin Oncol"},{"key":"2504_CR14","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1002\/cncr.25262","volume":"116","author":"V Gruenigen von","year":"2010","unstructured":"von Gruenigen V, Frasure H, Fusco N et al (2010) A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer 116:4735\u20134743","journal-title":"Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2504-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2504-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2504-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T21:27:23Z","timestamp":1597958843000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2504-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,8]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["2504"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2504-y","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,8]]}}}